ArticleJournal of hematology & oncology2019

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.

Weiping Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.